FIGURE 3.
Targeting IL-23 in autoimmune diseases. IL-23 inhibitors have been shown to be effective. Ustekinumab is an inhibitor targeting IL-23p40, Guselkumab and Risankizumab are specific inhibitors targeting IL-23p19. They each block the IL-23 signaling pathway by binding to the p40 subunit and p19 subunit, thereby inhibiting the immune response of TH17.